Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
MNPR logo MNPR
Upturn stock ratingUpturn stock rating
MNPR logo

Monopar Therapeutics Inc (MNPR)

Upturn stock ratingUpturn stock rating
$35.78
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: MNPR (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

5 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $61.02

1 Year Target Price $61.02

Analysts Price Target For last 52 week
$61.02Target price
Low$1.72
Current$35.78
high$54.3

Analysis of Past Performance

Type Stock
Historic Profit 258.52%
Avg. Invested days 61
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 205.47M USD
Price to earnings Ratio -
1Y Target Price 61.02
Price to earnings Ratio -
1Y Target Price 61.02
Volume (30-day avg) 5
Beta 1.01
52 Weeks Range 1.72 - 54.30
Updated Date 06/30/2025
52 Weeks Range 1.72 - 54.30
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.98

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -34.49%
Return on Equity (TTM) -54.27%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 200651196
Price to Sales(TTM) -
Enterprise Value 200651196
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -2.42
Shares Outstanding 6115210
Shares Floating 2902709
Shares Outstanding 6115210
Shares Floating 2902709
Percent Insiders 34.38
Percent Institutions 47.24

Analyst Ratings

Rating 3
Target Price 61.02
Buy 2
Strong Buy 2
Buy 2
Strong Buy 2
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Monopar Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics to treat cancer and other serious diseases. Founded in 2014, it has advanced multiple programs into clinical trials.

business area logo Core Business Areas

  • Oncology Therapeutics Development: Focuses on developing treatments for various cancers, including Validive for severe oral mucositis and camsirubicin for advanced soft tissue sarcoma.

leadership logo Leadership and Structure

The leadership team includes Chandler D. Robinson, MD (CEO), Andrew Mazar, PhD (CSO). The company has a board of directors overseeing its strategic direction.

Top Products and Market Share

overview logo Key Offerings

  • Validive (Clonidine Topical Solution): Being developed for the treatment of severe oral mucositis caused by cancer therapies. Competitors include Helsinn Healthcare SA (Aloxi).
  • Camsirubicin: A novel topoisomerase II inhibitor being developed for the treatment of advanced soft tissue sarcoma. Competitors include Eli Lilly and Company (Olaratumab).

Market Dynamics

industry overview logo Industry Overview

The oncology therapeutics market is large and competitive, driven by increasing cancer incidence and advancements in treatment modalities.

Positioning

Monopar focuses on niche areas within oncology, such as oral mucositis and soft tissue sarcoma, seeking to address unmet medical needs. Competitive advantages include its proprietary drug candidates and clinical development expertise.

Total Addressable Market (TAM)

The TAM for oral mucositis treatments is estimated to be in the hundreds of millions of dollars annually. The TAM for soft tissue sarcoma treatments is in the billions annually. Monopar is positioning itself to capture a portion of these markets with its targeted therapies.

Upturn SWOT Analysis

Strengths

  • Proprietary drug candidates
  • Experienced management team
  • Focus on unmet medical needs
  • Clinical-stage development programs

Weaknesses

  • Limited financial resources
  • Dependence on clinical trial outcomes
  • Small market capitalization
  • No currently marketed products

Opportunities

  • Positive clinical trial results
  • Partnerships with larger pharmaceutical companies
  • Expansion into new therapeutic areas
  • Regulatory approvals for key products

Threats

  • Clinical trial failures
  • Competition from established pharmaceutical companies
  • Changes in regulatory landscape
  • Economic downturn

Competitors and Market Share

competitor logo Key Competitors

  • LLY
  • HSIC

Competitive Landscape

Monopar is a smaller player compared to established pharmaceutical companies. Its competitive advantage lies in its focus on niche areas and proprietary drug candidates.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been driven by the advancement of clinical programs.

Future Projections: Future growth is dependent on clinical trial success and potential partnerships. Analyst estimates vary.

Recent Initiatives: Recent initiatives include advancing Validive and camsirubicin through clinical trials.

Summary

Monopar Therapeutics is a clinical-stage biopharmaceutical company with a focus on oncology. Its success hinges on clinical trial outcomes and securing partnerships to fund further development. The company faces stiff competition from larger, established pharmaceutical companies. Positive results could lead to significant growth, but failure to achieve clinical milestones could negatively impact the company. Its small market capitalization and dependence on clinical trial outcomes increase the risk for investors.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings (10-K, 10-Q)
  • Analyst Reports
  • Industry Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Market share data is approximate and based on available information.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Monopar Therapeutics Inc

Exchange NASDAQ
Headquaters Wilmette, IL, United States
IPO Launch date 2019-12-19
Co-Founder, CEO, President & Director Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc
Sector Healthcare
Industry Biotechnology
Full time employees 14
Full time employees 14

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.